Andrea Corcoran Form 3 Atea Pharmaceuticals / Andrea Corcoran ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Corcoran Andrea

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2020

3. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	500,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	100,000	(1)	D
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	33,004	(1)	D
Stock Option (Right to Buy)	(2)	12/08/2026	Common Stock	60,000	1.24	D
Stock Option (Right to Buy)	(3)	12/07/2027	Common Stock	60,000	1.53	D
Stock Option (Right to Buy)	(4)	12/13/2028	Common Stock	60,000	1.43	D
Stock Option (Right to Buy)	(5)	12/12/2029	Common Stock	60,000	1.85	D
Stock Option (Right to Buy)	(6)	08/02/2030	Common Stock	150,000	6.83	D

Explanation of Responses:

1. Each share of Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

2. The option is fully vested and exercisable.

3. The option vests and becomes exercisable in 36 equal monthly installments following November 30, 2017.

4. The option vests and becomes exercisable in 48 equal monthly installments following November 30, 2018.

5. The option vests and becomes exercisable in 48 equal monthly installments following November 30, 2019.

6. The option vests and becomes exercisable in 48 equal monthly installments following June 30, 2020.

Remarks:

CFO, General Counsel and Secretary Exhibit 24 - Power of Attorney.

	/s/ Andrea Corcoran	10/29/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.